Your trusted source for investing success

Tag: personalized medicine

3D Signatures Announces Change to Its Board of Directors

3D Signatures Announces Change to Its Board of Directors

3D Signatures Inc. (TSXV:DXD; OTCQB:TDSGF; FSE:3D0), announces that Helen Stevenson has resigned as a director of the Company effective immediately.
3DS wishes to thank Ms. Stevenson for her contribution, and wishes her all the best in her future endeavors.
The Company will take steps to fill Ms. Stevenson’s vacated seat as soon

3D Signatures Inc. Announces Grant of Stock Options

3D Signatures Inc. Announces Grant of Stock Options

3D Signatures Inc. (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) , announces that it has granted 10,000 incentive stock options (the “Options”) to an employee of 3D Signatures Holdings Inc., at an exercise price of $0.50 per share on June 26, 2017.
The Options are exercisable for a ten-year period from the date of grant

3D Signatures Advances Hodgkin’s Lymphoma Test

3D Signatures Advances Hodgkin’s Lymphoma Test

3D Signatures Inc. (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) (the “Company” or “3DS”), is pleased to announce that the clinical trial component (the “Clinical Trial”) of its Hodgkin’s lymphoma (“HL”) test (“Telo-HL”) validation program is successfully underway.

3D Signatures Inc. Reports Third Quarter 2017 Financial Results

3D Signatures Inc. Reports Third Quarter 2017 Financial Results

3D Signatures Inc.(TSXV:DXD,OTCQB:TDSGF) (the “Company” or “3DS”), today reported operational and financial results for its fiscal third quarter ended March 31, 2017.
Third Quarter Highlights

On January 4, 2017, 3DS announced that its common shares had started trading on the OTCQB Venture Market (“OTCQB”) and on the Frankfurt Stock Exchange under

3D Signatures Announces Change to Its Board of Directors

3D Signatures Announces Change to Its Board of Directors

3D Signatures Inc.(TSXV:DXD,OTCQB:TDSGF) (the “Company” or “3DS”), announced today that Ferenc Somogyvari will be stepping down from the Company’s Board of Directors, and will be joining the Company’s Clinical and Scientific Advisory Board (“CSAB”), effective immediately.
The Board acknowledges Mr. Somogyvari’s efforts and thanks him for his commitment and dedication to 3DS

3D Signatures’ Jason Flowerday

3D Signatures’ Jason Flowerday

3D Signatures’ CEO Jason Flowerday shares the company’s latest progress in validating the disruptive technology behind the TeloView Platform and the upcoming catalysts for 2017.

Enter Your Log In Credentials
×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network